Trial Profile
A Multicenter Randomized, Double-blind, Placebo and Positive Controlled ,Parallel Group ,Phase II Study to Access the Efficacy and Safety of SP2086 Treated Type 2 Diabetes Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Retagliptin (Primary) ; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 05 Nov 2013 New trial record